Evotec (EVO) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evotec (EVO) has outperformed Rezolute (RZLT) over the past year, losing 55.6% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $465.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | RZLT |
|---|---|---|
| Share price | $1.32 | $3.92 |
| Market cap | $469.11M | $465.58M |
| 1-day change | -8.97% | -6.67% |
| YTD return | -57.14% | +66.10% |
| 1-year return | -55.56% | -60.12% |
| 5-year return | -94.44% | -26.87% |
| EPS (TTM) | $-0.59 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-77.60M |
| 52-week high | $3.87 | $11.17 |
| 52-week low | $1.32 | $1.07 |
| Distance from 52-week high | -65.89% | -64.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +237.12% | +175.51% |
| Average volume | 109.16K | 1.66M |
| Shares outstanding | 355.39M | 118.77M |
| Employees | 4,379 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
EVO vs RZLT FAQ
Which is bigger, Evotec or Rezolute?
Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $465.58M for Rezolute (RZLT).
Which stock has performed better over the past year, EVO or RZLT?
EVO returned -55.56% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.